USFDA gives nod for GSK’s Ojjaara bone cancer therapy
The USFDA has approved GSK Plc’s oral therapy to treat anaemia in patients with myelofibrosis, a type of bone cancer.
Drugs
Health
Pharma
The USFDA has approved GSK Plc’s oral therapy to treat anaemia in patients with myelofibrosis, a type of bone cancer.